Dinu Stefan

Caen, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Caen, FR 

Overview

Dinu Stefan practices practicing medicine in Caen, France.

Their clinical expertise encompasses Glioma, Cerebral Hypoxia, Meningioma, and Gliomatosis Cerebri.

They are actively involved in clinical research, co-authoring 50 peer reviewed articles and participating in 7 clinical trials.

Locations

Caen, France
Other Locations
5, Avenue Foch, Brest, 29200, France
Toulouse, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Health Effects of CArdiac FluoRoscopy and MOderN RadIotherapy in PediatriCs - Radiotherapy (HARMONIC-RT)
Health Effects of CArdiac FluoRoscopy and MOderN RadIotherapy in PediatriCs - Radiotherapy (HARMONIC-RT)
Enrollment Status: Recruiting
Publish Date: August 03, 2026
Intervention Type: Other
A Phase I/II Multicenter Trial Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and the Anti-Programmed Death-ligand 1 (PD-L1) Durvalumab (Medi4736) for Patients With Recurrent Glioblastoma (STERIMGLI)
A Phase I/II Multicenter Trial Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and the Anti-Programmed Death-ligand 1 (PD-L1) Durvalumab (Medi4736) for Patients With Recurrent Glioblastoma (STERIMGLI)
Enrollment Status: Completed
Publish Date: April 14, 2026
Intervention Type: Radiation, Drug
Study Drug: Durvalumab
Study Phase: Phase 1/Phase 2
Phase III Randomised Trial Evaluating Treatment Intensification With Temozolomide in Adults With a Glioblastoma
Phase III Randomised Trial Evaluating Treatment Intensification With Temozolomide in Adults With a Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2026
Intervention Type: Drug
Study Drugs: Intensified Protocol, Stupp Protocol
Study Phase: Phase 3
Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients
Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug, Radiation
Study Drugs: Olaparib, Temozolomide (TMZ)
Study Phase: Phase 1/Phase 2
Radiotherapy of Multiple Brain Metastases Using AGuIX® Gadolinium-chelated Polysiloxane Based Nanoparticles: a Prospective Randomized Phase II Clinical Trial.
Radiotherapy of Multiple Brain Metastases Using AGuIX® Gadolinium-chelated Polysiloxane Based Nanoparticles: a Prospective Randomized Phase II Clinical Trial.
Enrollment Status: Unknown
Publish Date: June 14, 2024
Intervention Type: Radiation, Drug
Study Drug: AGulX
Study Phase: Phase 2
Phase I/II Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma
Phase I/II Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma
Enrollment Status: Completed
Publish Date: August 14, 2019
Intervention Type: Drug, Radiation
Study Phase: Phase 1/Phase 2
Prediction of Appearance of Late Cutaneous Side Effects After RadioTherapy
Prediction of Appearance of Late Cutaneous Side Effects After RadioTherapy
Enrollment Status: Completed
Publish Date: December 21, 2018
Intervention Type: Diagnostic test
Study Phase: Not Applicable
View 6 Less Clinical Trials

50 Total Publications

Radiobiology Contributions and Perspectives in Hadron Therapy, With a Focus on Carbon Ions: Report From the Workshop Hadron Therapy for Life, Caen, March 2025.
Radiobiology Contributions and Perspectives in Hadron Therapy, With a Focus on Carbon Ions: Report From the Workshop Hadron Therapy for Life, Caen, March 2025.
Journal: International journal of particle therapy
Published: November 06, 2025

Frequently Asked Questions about Dinu Stefan

Is Dinu Stefan a top-rated expert for Glioma?

MediFind is an objective health platform that identifies experts based on real-world data. Dinu Stefan is classified as an Experienced expert for Glioma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Dinu Stefan participate in research or clinical trials?

Yes. Dinu Stefan has published 50 articles and abstracts on conditions like Glioma. You can view a list of Dinu Stefan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Stefan's expertise for a condition
ConditionClose
        View All 19 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile